-
公开(公告)号：US20100003709A1
公开(公告)日：2010-01-07
申请号：US11793367
申请日：2005-12-13
申请人： Peter Reinemer , Heike Gielen-Haertwig , Ulrich Rosentreter , Volkhart Li , Axel Harrenga , Dietmar Schomburg , Karsten Niefind , Guido Hansen
发明人： Peter Reinemer , Heike Gielen-Haertwig , Ulrich Rosentreter , Volkhart Li , Axel Harrenga , Dietmar Schomburg , Karsten Niefind , Guido Hansen
IPC分类号： C12Q1/37 , C12N9/66 , G06G7/48 , C07D239/22
CPC分类号： C07D239/36 , C07K2299/00 , C12N9/6448 , C12Y304/21037
摘要： This invention relates to crystallised human neutrophil elastase and the use of its three-dimensional structure to design modulators for human neutrophil elastase.
摘要翻译： 本发明涉及结晶人嗜中性粒细胞弹性蛋白酶及其三维结构用于设计人嗜中性粒细胞弹性蛋白酶调节剂的用途。
-
公开(公告)号：US20130129739A1
公开(公告)日：2013-05-23
申请号：US13514996
申请日：2010-11-18
申请人： Christiane Ottto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Ottto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC分类号： C07K16/28
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体005-C04及其成熟形式，以及抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如 作为子宫内膜异位症，子宫腺肌症，非荷尔蒙女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20120321619A1
公开(公告)日：2012-12-20
申请号：US13514789
申请日：2010-12-08
申请人： Lars Linden , Yong-Jiang Cao , Gabriele Leder , Beatrix Stelte-ludwig , Axel Harrenga , Ricarda Finnern , Frank Dittmer , Anke Mayer-Bartschmid , Juergen Franz , Simone Greven , Jörg Willuda , Jan Tebbe
发明人： Lars Linden , Yong-Jiang Cao , Gabriele Leder , Beatrix Stelte-ludwig , Axel Harrenga , Ricarda Finnern , Frank Dittmer , Anke Mayer-Bartschmid , Juergen Franz , Simone Greven , Jörg Willuda , Jan Tebbe
IPC分类号： C07K16/30 , C12N15/85 , A61P35/04 , C12P21/08 , A61K39/395 , C12N1/21 , C12N15/13 , C12N5/10
CPC分类号： C07K16/30 , A61K39/39558 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/33 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
摘要： The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
摘要翻译： 本发明提供重组抗原结合区和抗体以及含有对多个肿瘤中过表达的膜锚定的29kDa C4,4a多肽具有特异性的此类抗原结合区的功能片段。 肺，结肠直肠，胰腺，前列腺，肾和乳腺癌。 因此，这些抗体可用于治疗这些和其他病症和病症。 本发明的抗体也可用于诊断领域，以及用于进一步研究C4.4a在与癌症相关疾病进展中的作用。 本发明还提供了编码前述抗体的核酸序列，含有该抗体的载体，药物组合物和具有使用说明书的试剂盒。
-
4.发明授权公开(公告)号：US09353186B2
公开(公告)日：2016-05-31
申请号：US14123517
申请日：2012-05-31
申请人： Christoph Freiberg , Christiane Otto , Lars Linden , Axel Harrenga , Mark Trautwein , Simone Greven , Andreas Wilmen
发明人： Christoph Freiberg , Christiane Otto , Lars Linden , Axel Harrenga , Mark Trautwein , Simone Greven , Andreas Wilmen
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
CPC分类号： C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/3015 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.
摘要翻译： 中和催乳素受体抗体Mat3和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如子宫内膜异位症，子宫腺肌症，非激素雌性避孕，良性乳腺疾病和 乳腺，泌乳抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，以及联合激素治疗中的联合抑制乳腺上皮细胞增殖和治疗和预防抗雌激素抵抗性乳腺癌。 该抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20140050743A1
公开(公告)日：2014-02-20
申请号：US13980431
申请日：2012-01-17
申请人： Frank Dittmer , Anja Buchmüller , Christoph Gerdes , Adrian Tersteegen , Mark Jean Gnoth , Lars Linden , Axel Harrenga , Joanna Grudzinska-Goebel , Mario Jeske , Martina Schäfer , Jörg Birkenfeld , Holger Paulsen , Ricarda Finnern , Anke Mayer-Bartschmid , Andrea Eicker , Simone Greven , Susanne Steinig
发明人： Frank Dittmer , Anja Buchmüller , Christoph Gerdes , Adrian Tersteegen , Mark Jean Gnoth , Lars Linden , Axel Harrenga , Joanna Grudzinska-Goebel , Mario Jeske , Martina Schäfer , Jörg Birkenfeld , Holger Paulsen , Ricarda Finnern , Anke Mayer-Bartschmid , Andrea Eicker , Simone Greven , Susanne Steinig
IPC分类号： C07K16/44
CPC分类号： C07K16/44 , A61K2039/505 , A61K2300/00 , C07K2317/55 , C07K2317/76
摘要： The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
摘要翻译： 本发明涉及抗原结合区，抗体，抗原结合抗体片段和抗体模拟物的鉴定和用途，其中和抗凝血剂在体外和/或体内的抗凝血作用。 本发明的抗体和功能片段和抗体模拟物可用于特异性地逆转抗凝血剂的药理学作用。 用于治疗（解毒剂）和/或诊断目的的FXa抑制剂。 本发明还提供了编码前述分子的核酸序列，含有该分子的载体，药物组合物和具有使用说明书的试剂盒。
-
公开(公告)号：US20130022606A1
公开(公告)日：2013-01-24
申请号：US13514995
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
IPC分类号： A61K39/395 , C07H21/00 , A61P15/00 , A61P13/08 , A61P17/14 , C12P21/02 , A61P15/14 , C12N15/63 , C12N5/10 , C12N1/19 , C12N1/21 , C07K16/28 , A61P15/18
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 006-H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体006-H07和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性病症和适应症的用途，例如子宫内膜异位症，子宫腺肌症， 激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20090170766A1
公开(公告)日：2009-07-02
申请号：US12224759
申请日：2007-03-01
申请人： Felix Oehme , Heiner Apeler , Frank Dittmer , Jürgen Franz , Axel Harrenga , Michael Sperzel , Simone Greven , Jürgen Lenz
发明人： Felix Oehme , Heiner Apeler , Frank Dittmer , Jürgen Franz , Axel Harrenga , Michael Sperzel , Simone Greven , Jürgen Lenz
CPC分类号： C07K14/8114
摘要： The present invention relates to chimeras of human tissue factor inhibitor domain 1 with natural and non-natural Kunitz domains, and their preparation and use.
摘要翻译： 本发明涉及具有天然和非天然Kunitz结构域的人组织因子抑制剂结构域1的嵌合体及其制备和用途。
-
公开(公告)号：US20130272968A1
公开(公告)日：2013-10-17
申请号：US13514992
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC分类号： A61K39/395 , A61K45/06
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体006-H08以及其成熟形式，以及抗原结合片段，含有它们的药物组合物及其在治疗或预防良性病症和由催乳素受体介导的适应症中的用途 子宫内膜异位症，子宫腺肌症，非激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20120321632A1
公开(公告)日：2012-12-20
申请号：US13514991
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The composition of the invention blocks prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及含有一种或多种中和催乳素受体抗体和抗原结合片段的药物组合物，以及它们在治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如子宫内膜异位，子宫腺肌症，非激素雌性避孕 ，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，以及联合激素治疗中的抑制乳腺上皮细胞增殖的联合治疗。 本发明的组合物阻断催乳素受体介导的信号传导。
-
公开(公告)号：US09241989B2
公开(公告)日：2016-01-26
申请号：US13514996
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC分类号： A61K39/395 , C07K16/28 , A61K45/06 , A61K39/00
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体005-C04及其成熟形式，以及抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如 作为子宫内膜异位症，子宫腺肌症，非荷尔蒙女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.054 秒)
